DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 5,256,410
|Title:||Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon|
|Abstract:||Human squamous cell carcinoma is successfully treated by intralesional administration of recombinant human interferon alpha-2b.|
|Inventor(s):||Tanner; Daniel J. (Brooklyn, NY), Peets; Edwin A. (New York, NY), Smiles; Kenneth A. (Novato, CA)|
|Assignee:||Schering Corporation (Kenilworth, NJ)|
|Patent Claims:||1. A method for treating human squamous cell carcinoma comprising intralesionally administering to a human in need of such treatment a sufficient amount of a purified
recombinant human alpha-2 interferon to be effective as an anti-squamous cell carcinoma agent.
2. A method of claim 1 wherein the alpha-2 interferon is recombinant human interferon alfa-2b.
3. A method of claim 1 wherein treatment is effected by administering a dosage of 0.1 to 10.times.10.sup.6 International Units of recombinant human alpha-2 interfereon by injection.
4. A method of claim 1 wherein the dosage is 1.5.times.10.sup.6 International Units.
5. A method of claim 4 wherein the dosage is administered three days a week for three weeks.
Summary for Patent: ⤷ Free Forever Trial
|PCT Filed||November 29, 1989||PCT Application Number:||PCT/US89/05287|
|PCT Publication Date:||June 14, 1990||PCT Publication Number:||WO90/06135|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||⤷ Free Forever Trial||Schering Corporation (Kenilworth, NJ)||2010-10-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||⤷ Free Forever Trial||Schering Corporation (Kenilworth, NJ)||2010-10-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||⤷ Free Forever Trial||Schering Corporation (Kenilworth, NJ)||2010-10-26||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|Austria||92333||⤷ Free Forever Trial|
|Australia||4802590||⤷ Free Forever Trial|
|Australia||634511||⤷ Free Forever Trial|
|Canada||2004202||⤷ Free Forever Trial|
|Germany||68908119||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.